Chronic Myelogenous Leukemia (CML) Latest Advances

Find the Latest Research About Chronic Myelogenous Leukemia (CML)

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26186 publications

Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.

Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.

Journal: Drug research

Published: June 19, 2026

Combined treatment of zingerone and nilotinib induces cytotoxicity and reverses nilotinib resistance in chronic myeloid leukemia cells via inhibition of the PI3K signaling.

Combined treatment of zingerone and nilotinib induces cytotoxicity and reverses nilotinib resistance in chronic myeloid leukemia cells via inhibition of the PI3K signaling.

Journal: Toxicology mechanisms and methods

Published: June 18, 2026

Treatment and burden of patients with chronic myeloid leukemia in Japan: A retrospective claims database analysis.

Treatment and burden of patients with chronic myeloid leukemia in Japan: A retrospective claims database analysis.

Journal: Internal medicine (Tokyo, Japan)

Published: June 17, 2026

Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation.

Mitochondrial translocation of p210 BCR-ABL rewires downstream signaling by selectively suppressing ERK activation.

Journal: Biochemical and biophysical research communications

Published: June 16, 2026

FNBP1 in Chronic Myeloid Leukemia: Spatial Association with BCR-ABL and Potential Implications for Targeted Therapy.

FNBP1 in Chronic Myeloid Leukemia: Spatial Association with BCR-ABL and Potential Implications for Targeted Therapy.

Journal: Experimental oncology

Published: June 12, 2026

Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amid limited tyrosine kinase inhibitor access.

Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amid limited tyrosine kinase inhibitor access.

Journal: The Journal of international medical research

Published: June 10, 2026

Integrated Cytogenetic and FISH Profiling Reveals inv(16) Dominance and Cryptic 11q23 Lesions in AML and ALL: Clinical Significance from a Referral Cohort.

Integrated Cytogenetic and FISH Profiling Reveals inv(16) Dominance and Cryptic 11q23 Lesions in AML and ALL: Clinical Significance from a Referral Cohort.

Journal: Journal of the Association of Genetic Technologists

Published: June 05, 2026

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

Journal: The New England journal of medicine

Published: June 03, 2026

Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

Journal: The New England journal of medicine

Published: June 03, 2026

Preneoplastic and Neoplastic Small Lymphocytic Proliferations Concurrent with Acute Myeloid Leukemia: A Report of Four Cases

Preneoplastic and Neoplastic Small Lymphocytic Proliferations Concurrent with Acute Myeloid Leukemia: A Report of Four Cases

Journal: Zhongguo shi yan xue ye xue za zhi

Published: June 02, 2026

Prepubertal Initiation of Imatinib is Associated with Reduced Final Height in Children with Chronic Myeloid Leukemia.

Prepubertal Initiation of Imatinib is Associated with Reduced Final Height in Children with Chronic Myeloid Leukemia.

Journal: Pediatric hematology and oncology

Published: June 01, 2026

Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment - a narrative review.

Polypharmacy, polypharmacology, and polypharmacotherapy: clarifying definitions and complementary roles in cancer treatment - a narrative review.

Journal: Expert review of anticancer therapy

Published: May 30, 2026

Showing 1-12 of 26,186

Last Updated: 06/30/2026